New Two-Drug attack tested against Tough-to-Treat cancers
NCT ID NCT04332653
Summary
This study tested a new combination of two drugs, NT-I7 and pembrolizumab, for people with advanced solid tumors that had returned or stopped responding to prior therapies. The main goals were to find a safe dose and see if the combination could shrink tumors in several hard-to-treat cancers, including certain types of breast, lung, colorectal, pancreatic, and ovarian cancer. Researchers also looked at how the treatment affected immune cells inside the tumors.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PANCREATIC CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Barbara Ann Karmanos Cancer Institute
Detroit, Michigan, 48201, United States
-
Duke University Medical Center
Durham, North Carolina, 27710, United States
-
Fox Chase Cancer Center
Philadelphia, Pennsylvania, 19111, United States
-
MD Anderson Cancer Center
Houston, Texas, 77030, United States
-
Mary Crowley Cancer Research
Dallas, Texas, 75230, United States
-
Moffit Cancer Center
Tampa, Florida, 33612, United States
-
Sarah Cannon Research Institute
Nashville, Tennessee, 37211, United States
-
Washington University School of Medicine in St. Louis
St Louis, Missouri, 63110, United States
Conditions
Explore the condition pages connected to this study.